Journal of Clinical Oncology
Articles in this Issue
Trends and disparities in procedure-related mortality among older U.S. adults with digestive system malignancies: A 24-year analysis of the CDC WONDER database.
e15717 Background: Older adults with digestive system malignancies (DSM) frequently undergo diagnostic and therapeuticproc...
Treatment outcomes and unmet needs in patients with acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy (IC): A systematic literature review (SLR).
e18517 Background: AML is an aggressive cancer that accounts for around one third of all leukemias. Approximately 42% of p...
Emerging demographic and geographic disparities in cerebrovascular mortality among U.S. patients with colorectal cancer: A CDC WONDER analysis, 1999–2023.
e15730 Background: Colorectal cancer (CRC) is the third most common malignancy globally, with rising incidence in adults u...
PhaseX as a phase 0.9 translational platform to de-risk BiTE immunotherapy through mechanistic patient explant profiling.
2615 Background: Bispecific T-cell engagers (BiTEs) redirect cytotoxic T cells to tumor cells, but responses in solid tumo...
Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL).
7042 Background: While the association between AFib and CLL has been reported, real-world evidence on its clinical and eco...
Molecular classification of neuroendocrine carcinoma of the bladder.
4628 Background: Neuroendocrine carcinoma (NEC) of the bladder is a rare and aggressive cancer with limited treatment opti...
Real-world risk-assessment using the Mirai breast cancer risk prediction model: A preliminary analysis of patients from a comprehensive cancer screening clinic.
e22560 Background: The current standard of care for breast cancer risk assessments is the Tyrer-Cuzick (TC) model, which r...
Urinary tumor DNA as a biomarker of pathologic response and molecular residual disease in muscle-invasive bladder cancer: A systematic review.
e15055 Background: Despite advances in multimodal therapy, recurrence after curative-intent treatment for muscle-invasive...
Hepatic artery infusion chemotherapy plus adebrelimab and bevacizumab as first-line treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus.
e16165 Background: Advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is usually associa...
Effects of multimodal local therapy on survival in gastric cancer leptomeningeal metastases.
e14022 Background: Leptomeningeal metastasis (LM) from gastric cancer represents a terminal condition with poor prognosis,...
Impact of FGFR3 pathway activation in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy.
4596 Background: The prognostic value of FGFR3 pathway activation in patients with muscle-invasive bladder cancer (MIBC) t...
A phase II, single-arm, exploratory study of GEMOX combined with tislelizumab and donafenib in the perioperative treatment of potentially resectable intrahepatic cholangiocarcinoma with high recurrence risk.
TPS11199 Background: Biliary tract cancer (BTC) is characterized by strong invasiveness and poor prognosis, with a metasta...
Socioeconomic disparities in access to biomarker testing for gastrointestinal cancers: A nationwide patient-reported outcomes analysis.
e23261 Background: Recent advancements in biomarker technology, in conjunction with growing patient awareness, are notably...
Beyond convolution: Attention-driven vision transformer modeling for breast cancer detection on mammography.
575 Background: Breast cancer is the most commonly diagnosed malignancy among women worldwide, and screening mammography r...
Clinical efficacy of tislelizumab in combination with gemcitabine and nab-paclitaxel and chemoresistance analysis in borderline resectable pancreatic cancer: A prospective pilot study.
2630 Background: Neoadjuvant therapy has been demonstrated to improve the survival outcomes of patients with borderline re...
Assessment of the role of rapid drug desensitization to treat cancer patient with infusion-related allergic reactions.
11156 Background: Rapid Drug Desensitization (RDD) as The Castells protocol is based on progressively increasing concentra...
Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy.
621 Background: Neoadjuvant outcomes are variable in human epidermal growth factor receptor 2-positive (HER2+) early breas...
Prevalence, tumor characteristics, and clinical impact of <i>LZTR1</i> pathogenic variants in a large, pan-cancer cohort.
10621 Background: Heterozygous germline pathogenic/likely pathogenic (P/LP) loss-of-function (LOF) variants in...
The effect of adjuvant carboplatin-based chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials.
e12523 Background: Carboplatin has been shown to improve pathologic complete response and disease-free survival (DFS) in p...
A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist antibody-drug conjugate (ADC), in patients with advanced/metastatic solid tumors.
TPS3159 Background: While immunotherapies have improved treatment for patients with advanced/metastatic solid tumors, ther...
A phase 2 study of plinabulin (Plin)/docetaxel (Doc) plus pembrolizumab (Pemb) in metastatic NSCLC (mNSCLC) after acquired resistance (AR) to anti–PD-1/L1 alone or in chemotherapy combination: Efficacy and immunophenotyping.
8567 Background: PD-1/L1 inhibitors have become a part of 1L treatment for EGFR/ALK wild-type NSCLC. However, >60% pati...
Effect of melatonin on the fatigue, sleep, and depression symptom cluster in breast cancer according to dosage and treatment phase: A systematic review and meta-analysis.
e24112 Background: Patients with breast cancer (BC) frequently experience a debilitating symptom cluster of sleep disturba...
Baseline predictors of early mortality in patients with PD-L1–high advanced NSCLC treated with first-line immunotherapy.
e20691 Background: Single-agent immunotherapy (IT) is the standard first-line treatment for patients (pts) with advanced n...
Effect of transanal vs. laparoscopic total mesorectal excision on 5-year overall survival in patients with rectal cancer: The TaLaR trial.
3631 Background: Transanal total mesorectal excision (taTME) has emerged as a widely adopted surgical approach for rectal...
Comparative performance of large language model derived and clinician documented ECOG-PS in predicting clinical outcomes in head and neck squamous cell carcinoma (HNSCC) undergoing concurrent chemoradiation (CRT).
e23101 Background: Clinician-documented ECOG-PS (dECOG-PS) often overestimates true ECOG-PS. The ability of large language...